全文获取类型
收费全文 | 1869篇 |
免费 | 123篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 152篇 |
妇产科学 | 17篇 |
基础医学 | 245篇 |
口腔科学 | 47篇 |
临床医学 | 177篇 |
内科学 | 478篇 |
皮肤病学 | 25篇 |
神经病学 | 76篇 |
特种医学 | 471篇 |
外科学 | 106篇 |
综合类 | 30篇 |
预防医学 | 53篇 |
眼科学 | 17篇 |
药学 | 56篇 |
中国医学 | 3篇 |
肿瘤学 | 60篇 |
出版年
2022年 | 6篇 |
2021年 | 8篇 |
2020年 | 11篇 |
2019年 | 9篇 |
2018年 | 18篇 |
2017年 | 15篇 |
2016年 | 23篇 |
2015年 | 28篇 |
2014年 | 27篇 |
2013年 | 60篇 |
2012年 | 32篇 |
2011年 | 34篇 |
2010年 | 78篇 |
2009年 | 63篇 |
2008年 | 44篇 |
2007年 | 37篇 |
2006年 | 37篇 |
2005年 | 34篇 |
2004年 | 32篇 |
2003年 | 25篇 |
2002年 | 34篇 |
2001年 | 31篇 |
2000年 | 37篇 |
1999年 | 35篇 |
1998年 | 134篇 |
1997年 | 121篇 |
1996年 | 129篇 |
1995年 | 93篇 |
1994年 | 76篇 |
1993年 | 83篇 |
1992年 | 35篇 |
1991年 | 31篇 |
1990年 | 23篇 |
1989年 | 68篇 |
1988年 | 52篇 |
1987年 | 53篇 |
1986年 | 47篇 |
1985年 | 49篇 |
1984年 | 28篇 |
1983年 | 35篇 |
1982年 | 36篇 |
1981年 | 22篇 |
1980年 | 36篇 |
1979年 | 15篇 |
1978年 | 16篇 |
1977年 | 18篇 |
1976年 | 23篇 |
1975年 | 24篇 |
1971年 | 3篇 |
1966年 | 2篇 |
排序方式: 共有2014条查询结果,搜索用时 31 毫秒
11.
J J Day I Grant J H Atkinson L T Brysk J A McCutchan J R Hesselink R K Heaton J D Weinrich S A Spector D D Richman 《The Journal of neuropsychiatry and clinical neurosciences》1992,4(1):15-20
In a prospective study to determine the incidence of clinical dementia in patients with AIDS and ARC, 29 men and 3 women, 19 with ARC and 13 with AIDS, were examined neurologically and neuropsychologically every 6 months for 2 years during a placebo-controlled zidovudine (AZT) licensing trial. Most received two MRI brain scans. Although no patient was clinically demented at baseline, 9 (28%) developed dementia during the 2 years. Progression to dementia was associated with neuropsychological deterioration and with worsening on MRI during a preceding 6-month period, but not with baseline treatment group assignment. The results suggest that patients at CDC Stage IV who do not receive antiretroviral treatment earlier in their illness may develop clinical dementia at an annual rate of about 14%. 相似文献
12.
Miguel JA Láinez 《Neuropsychiatric Disease and Treatment》2006,2(3):247-259
Migraine is a common, disabling disorder associated with considerable personal and societal burden. Current guidelines recommend triptans for the acute treatment of migraine unlikely to respond to less effective therapies. Rizatriptan is a second-generation triptan available in tablet or orally disintegrating tablet (wafer) formulations that offers several advantages over other members of its class. Rizatriptan is rapidly absorbed from the gastrointestinal tract and achieves maximum plasma concentrations more quickly than other triptans, providing rapid pain relief. Clinical trials have shown that rizatriptan is at least as effective or superior to other oral migraine-specific agents in the acute treatment of migraine, and has more consistent long-term efficacy across multiple migraine attacks. Rizatriptan has a favorable tolerability profile, and patients have reported greater satisfaction and a preference for rizatriptan over other migraine-specific agents. Improvements in quality of life reported with rizatriptan are consistent with its favorable efficacy and tolerability profiles. Notably, multi-attribute decision models that combine clinical data with patient- and physician-reported treatment preferences have identified rizatriptan as one of three triptans closest to a hypothetical “ideal”. The efficacy and tolerability of rizatriptan for the acute treatment of migraine have thus been well established. 相似文献
13.
We report an adult female with a rare giant choledochal cyst. The patient presented following a normal pregnancy with the classical triad of an abdominal mass associated with jaundice and right upper quadrant abdominal pain. The cyst was excised using an intramural technique and biliary reconstruction achieved with a Roux-en-Y hepaticojejunostomy. Our patient has remained well with no evidence of malignancy over a 12 year review period. The aetiology and current management of this condition are discussed. 相似文献
14.
15.
Na+ dependence of in vitro pancreatic amylase release 总被引:1,自引:0,他引:1
16.
Determination of optimal cryoprotectants and procedures for their addition and removal from human spermatozoa 总被引:9,自引:7,他引:9
The objective was to test the hypothesis that the optimal cryoprotective
agent for cryopreservation of human spermatozoa would be a solute for which
cells have the highest plasma membrane permeability, resulting in the least
amount of volume excursion during its addition and removal. To test this
hypothesis, theoretical simulations were performed using membrane
permeability coefficients to predict optimal procedures for the addition
and removal of a cryoprotectant. Simulations were performed using data from
four different cryoprotectants: (i) glycerol, (ii) dimethyl sulphoxide,
(iii) propylene glycol and (iv) ethylene glycol. Thermodynamic formulations
were applied to determine approaches for the addition and removal of 1 M
and 2 M final concentrations of cryoprotectant, allowing the spermatozoa to
maintain a cell volume within their osmotic tolerance limits. Based on
these data, ethylene glycol was predicted to be optimal for minimizing
volume excursions among the solutes evaluated. These predictions were then
experimentally tested using glycerol as the control cryoprotectant and
ethylene glycol as the experimental cryoprotectant. The results indicate
that there was a higher (P < 0.05) recovery of motile spermatozoa after
cryopreservation when using 1 M ethylene glycol than with 1 M glycerol,
supporting the hypothesis that use of the cryoprotectant for which the cell
has the highest permeability will result in higher cell survival.
相似文献
17.
Laukkanen T Carr JK Janssens W Liitsola K Gotte D McCutchan FE Op de Coul E Cornelissen M Heyndrickx L van der Groen G Salminen MO 《Virology》2000,269(1):95-104
For reliable classification of HIV-1 strains appropriate reference sequences are needed. The HIV-1 genetic subtype F has a wide geographic spread, causing significant epidemics in South America, Africa, and some regions of Europe. Previously only two full-length sequences of each of the HIV-1 subtype F subclusters F1 and F2 have been described. To extend the knowledge of subtype F variation on a complete genome level, three new virtually full-length F1 sequences were cloned and sequenced, two from Africa and one from South America. Comparison of the new and previously described sequences showed that monophyletic clustering of the subcluster F1 of subtype F is consistent and highly supported in all genome regions. Two additional full-length strains were shown to be mosaics of subtypes F and D. These epidemiologically unrelated F/D sequences showed similar chimeric structure, suggesting that they may represent a previously undescribed circulating recombinant form (CRF). This was supported by partial sequences from three additional unlinked F/D recombinants. Genetic distances in the phylogenetic trees suggest that the recombination event leading to the putative CRF occurred relatively long ago, close to the divergence of the F1 and F2 subclusters. Furthermore, all five F/D recombinants are linked to the Democratic Republic of Congo, suggesting that the original recombination event took place in central Africa. 相似文献
18.
Comparison of isolation of Haemophilus vaginalis (Corynebacterium vaginale) from peptone-starch-dextrose agar and Columbia colistin-nalidoxic acid agar.
下载免费PDF全文
![点击此处可从《Journal of clinical microbiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
A total of 447 cervical or vaginal specimens were inoculated in parallel onto peptone-starch-dextrose (PSD) and Columbia colistin (10 mg/ml)-nalidixic acid (15 mug/ml) (CNA) agar and were incubated for 48 h at 35 degrees C in an atmosphere with 2 to 10% CO2. One hundred (22.4%) of the cultures were positive for Haemophilus vaginalis. Forty-eight of the isolates were recovered from both PSD and Columbia CNA agar, five from PSD only, and 47 from Columbia CNA agar only (P less than 0.001). On Columbia CNA agar, 76 of the isolates were detected after 24 h of incubation, and the remainder were detected within 4 days of incubation. 相似文献
19.
20.